EEF1A1 and metabolic dysfunction-associated steatotic liver disease: To our knowledge, this is the first report of the potential benefit of inhibition of EEF1A1, or chemical inhibition of peptide elongation, in an in vivo model of ER stress‐related disease such as NAFLD.